{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:24:09Z","timestamp":1790346249314,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:00:00Z","timestamp":1420675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine the dopamine receptor subtype 2 (DR2) <jats:styled-content style=\"fixed-case\">mRNA<\/jats:styled-content> levels and protein expression and to evaluate the effect of adjuvant cabergoline therapy on tumour volume (<jats:styled-content style=\"fixed-case\">TV<\/jats:styled-content>) in patients with postoperative residual nonfunctioning pituitary adenoma (<jats:styled-content style=\"fixed-case\">NFPA<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The <jats:styled-content style=\"fixed-case\">mRNA<\/jats:styled-content> expression was quantified by real\u2010time RT\u2010PCR (TaqMan<jats:sup>\u00ae<\/jats:sup>), and protein expression was evaluated by immunohistochemistry. Tumours were classified according to the percentage of immunostained cells for DR2 as scores 1 (&lt;50% of stained cells) or 2 (\u226550%). Cabergoline was started at least 6\u00a0months after surgery in nine patients with residual tumours (3\u00a0mg\/week). The cabergoline effect was prospectively evaluated by magnetic resonance imaging using three\u2010dimensional volume calculation. TV reduction &gt;25% was considered significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The DR2 <jats:styled-content style=\"fixed-case\">mRNA<\/jats:styled-content> expression was variable but was observed in 100% of the samples (<jats:italic>N<\/jats:italic>\u00a0=\u00a020). DR2 protein expression was also observed in all the tumours (<jats:italic>N<\/jats:italic>\u00a0=\u00a034). Twenty\u2010nine tumours (85%) were classified as score 2. The median DR2 <jats:styled-content style=\"fixed-case\">mRNA<\/jats:styled-content> expression was higher in the tumours classified as score 2 compared with score 1 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b7007). TV reduction with cabergoline therapy was observed in 67% of the patients (6\/9). The median TV before and after 6\u00a0months of treatment was 1\u00b790\u00a0cm<jats:sup>3<\/jats:sup> (0\u00b761\u20138\u00b774) and 1\u00b769\u00a0cm<jats:sup>3<\/jats:sup> (0\u00b736\u20134\u00b720) [<jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b702], respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, <jats:styled-content style=\"fixed-case\">DR<\/jats:styled-content>2 is expressed in all adenomas and the majority of the patients in this study displayed tumour shrinkage on cabergoline (<jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content>) therapy. Thus, <jats:styled-content style=\"fixed-case\">CAB<\/jats:styled-content> might be useful in adjuvant therapy in <jats:styled-content style=\"fixed-case\">NFPA<\/jats:styled-content> patients with residual tumours after surgery.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.12684","type":"journal-article","created":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T04:13:35Z","timestamp":1416629615000},"page":"739-746","source":"Crossref","is-referenced-by-count":52,"title":["Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and <i>in vivo<\/i> response to cabergoline therapy"],"prefix":"10.1111","volume":"82","author":[{"given":"Leonardo","family":"Vieira Neto","sequence":"first","affiliation":[{"name":"Neuroendocrinology Research Center\/Endocrinology Section Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"},{"name":"Endocrinology Unit Hospital Federal da Lagoa Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center\/Endocrinology Section Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline B.","family":"Moraes","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center\/Endocrinology Section Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro M.","family":"Colli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Medical School of Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center\/Endocrinology Section Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"},{"name":"Endocrinology Unit Hospital Federal de Bonsucesso Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelma Ver\u00f4nica","family":"Marques","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center\/Endocrinology Section Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson L.","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Department of Radiology Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"de Castro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Medical School of Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Maeda","family":"Takiya","sequence":"additional","affiliation":[{"name":"Instituto de Biof\u00edsica Carlos Chagas Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center\/Endocrinology Section Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02298"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2552"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3171\/JNS\/2008\/108\/3\/0525"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-200207000-00020"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-007-0083-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000095526"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0471"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02313"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1826"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030859"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.79.5.1416"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077406"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-268"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)01423-4"},{"key":"e_1_2_7_17_1","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg L.E.","year":"2013","journal-title":"Journal of Endocrinological Investigation"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322787"},{"key":"e_1_2_7_19_1","first-page":"580","article-title":"Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT\u2010PCR and immunohistochemistry","volume":"35","author":"Wildemberg L.E.","year":"2012","journal-title":"Journal of Endocrinological Investigation"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10278-004-1014-6"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-199207000-00004"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03755.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-07-0271"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0316-1"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0380-1"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-011-0701-6"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0403-y"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02295.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jcem.83.1.4493","article-title":"Correlation of scintigraphic results using 123I\u2010methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas","volume":"83","author":"Ferone D.","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00951.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.1880060421"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2095"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02990.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02334"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2006.104.6.884"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.12684","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.12684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T15:23:37Z","timestamp":1695482617000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.12684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,8]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/cen.12684"],"URL":"https:\/\/doi.org\/10.1111\/cen.12684","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,8]]}}}